Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
This executive order directs the Administration to pursue most-favored-nation prescription drug pricing, requiring pharmaceutical manufacturers to offer U.S. patients prices comparable to other developed nations or face potential rulemaking, importation waivers, antitrust enforcement, export reviews, and FDA approval modifications. It establishes a 30-day deadline for HHS to communicate price targets to drug makers, with escalating measures if progress is not achieved.